As a result of, in accordance with previously announced information, the directed issue of 1,200,000,000 Class B shares resolved on 17 April 2026 and the directed issue of an additional number of 375,466,222 Class B shares resolved on 23 April 2026, the number of shares and votes in Episurf Medical AB (publ) ("Episurf") has changed.
Through the above-mentioned changes, the total number of shares in Episurf amounts to 4,385,960,612, of which 473,357 are Class A shares and 4,385,487,255 are Class B shares, and the total number of votes in Episurf amounts to 4,386,907,326.
For further information, please contact:
Jens Andersson, CEO, Episurf Medical
Tel: +46(0) 768 55 67 02
Email jens.andersson@episurf.com
This information is information that Episurf Medical AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact person set out above, at 11:45 CET on 30 April 2026.
About Episurf
Episurf Medical is a real estate company with exposure to a diversified portfolio of real estate assets. The Company aims to create value growth through the acquisition and management of Nordic properties. The Company also conducts medtech operations based on the individualized implant Episealer® and associated surgical instruments, used to treat cartilage damage in joints. Episurf Medical's head office is located in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, visit the company's website: www.episurf.com.